Fig. 1 · Structure

Documents & Downloads

IWR-1-endo

Cat. No. A12737 CAS 1127442-82-3

Wnt inhibitor

IWR-1-endo is a potent inhibitor of the Wnt response, blocking a cell-based Wnt/β-catenin pathway reporter response with an IC50 value of 180 nM. Wnt proteins bind to receptors on the cell surface, initiating a signaling cascade that leads to β-catenin activation of gene transcription.

In Stock

Publications for IWR-1-endo

2 publications citing this product

  1. Yuichi Akaba, .et al. , iScience, 2025, Oct 16;28(11):113789 PMID: 41244585
  2. Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

IWR-1-endo increased Axin1 and tankyrase 1/2 protein abundance in MDA-MB-231 cells. This cellular response supports its use to study the tankyrase–Axin/Wnt pathway; it is not a direct enzyme-binding measurement. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Wnt (L-cells expressing Wnt3A) 180 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 GI50 > 100 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 24950489]
HEK293 IC50 136 μM Inhibition of Tankyrase in human HEK293 cells assessed as inhibition of Wnt pathway by Wnt3a-induced STF assay [PMID: 23316926]
HEK-293T IC50 26 nM Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay [PMID: 22191557]
HepG2 GI50 95.4 μM Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay [PMID: 24950489]
HT-29 GI50 > 100 μM Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay [PMID: 24950489]
HT-29 IC50 24.4 μM Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control [PMID: 24950489]
HT-29 IC50 9.52 μM Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method [PMID: 34062253]
LoVo GI50 63.1 μM Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay [PMID: 24950489]
SW480 IC50 0.25 μM Inhibition of tankyrase in human SW480 cells assessed as degradation of beta catenin after 40 to 48 hrs [PMID: 23701517]
SW480 EC50 2.5 μM Inhibition of tankyrase in human SW480 cells assessed as accumulation of axin2 after 24 hrs by Hoechst dye-based method [PMID: 23701517]

10 records · Scroll to view more

In Vitro Studies

In a Wnt-responsive L-cell reporter assay, endo-IWR-1 had a reported EC50 of 0.2 μM. Exo-IWR was 25-fold less active (EC50 5 μM), showing that the two forms should not be treated as interchangeable. [2]

At 5 μM, IWR-1-endo attenuated Wnt3a-stimulated migration of MDA-MB-231 cells over 14 h, while basal motility was not reduced. This result is conditional on Wnt stimulation and the tested culture conditions. [1]

Endo/exo comparison in a Wnt reporter assay

Cell-based study · Mouse L-cells expressing Wnt3A and control and Wnt-responsive reporters [2]

Endo-IWR-1 suppressed Wnt reporter activity more potently than exo-IWR. The paper labels these values EC50, rather than an enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of Wnt/β-catenin reporter responseEC50 0.2 μM[2]
Exo-IWR comparator and stereochemical sensitivityEC50; relative activity exo-IWR (51): 5 μM; 25-fold less active than endo-IWR (1)[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; no treatment concentration substituted for EC50
Method
Cell-based luciferase reporter assay
Reported limits
Assay duration, vehicle and replicate number are not specified in the selected paper’s assay footnote or figure captions.
Methods and source locations

Compound reported in the paper: IWR-1-endo; Compound label in the paper: endo-IWR 1 (compound 1)

Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.

Figures 1–2; norbornyl SAR paragraph; footnote 6

Inhibition of Wnt/β-catenin reporter response: Reporter assay; value printed in Figure 1 — Figure 1 (compound 1); footnote 6

Exo-IWR comparator and stereochemical sensitivity: Figure 2 printed value and accompanying SAR text; comparator is not the product — Figure 2; norbornyl SAR paragraph

Axin1 accumulation in breast cancer cells

Cell-based study · Human MDA-MB-231 breast cancer cells [1]

IWR-1-endo increased Axin1 and tankyrase 1/2 protein abundance relative to DMSO, with or without Wnt3a. This cellular experiment does not measure enzyme affinity or establish direct binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Axin1 and TNKS1/TNKS2 abundanceQualitative immunoblot result Increased versus DMSO[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
Overnight compound treatment; Wnt3a-conditioned medium for 4 h
Method
Immunoblot of total cell lysates; actin loading control
Vehicle
DMSO
Co-treatment
Parallel control-conditioned and Wnt3a-conditioned medium conditions; XAV939 is a separate comparator.
Reported limits
Exact overnight hours and replicate number for Figure 1D are not stated in its caption.
Methods and source locations

Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1-endo

Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.

Figure 1D and caption; Results first subsection; Materials and Methods: Compounds, Immunoblotting

Axin1 and TNKS1/TNKS2 abundance: Anti-Axin1 and anti-tankyrase immunoblot; actin loading control — Figure 1D; corresponding Results paragraph

Wnt-stimulated versus basal migration

Cell-based study · Confluent human MDA-MB-231 monolayers [1]

IWR-1 attenuated Wnt3a-induced wound closure at 14 h but did not reduce basal motility in the absence of Wnt3a.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Wnt3a-stimulated and basal wound closureQualitative comparison Wnt3a-stimulated migration attenuated; basal motility not reduced[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
14 h
Method
Wound-healing assay; cell-free area quantified with ImageJ relative to time 0
Vehicle
DMSO
Co-treatment
Control or Wnt3a-conditioned medium with 2.5% FBS; XAV939 tested separately.
Reported limits
Replicate number and error-bar definition for Figure 4 are not given in its caption; no numerical percentage is extracted.
Methods and source locations

Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1 (paper reagent: IWR-1-endo)

Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.

Figure 4A–B and caption; Results: XAV939 inhibits Wnt3A-induced cell migration in MDA-MB-231 breast cancer cells; Materials and Methods: Wound healing and cell migration assay

Wnt3a-stimulated and basal wound closure: Matched DMSO, control-medium and Wnt3a-medium comparisons at 14 h; images and graph viewed — Figure 4A–B; corresponding Results paragraph

In Vivo Studies

In adult zebrafish, 10 μM IWR-1 in aquarium water inhibited caudal-fin regeneration during a 7-day exposure. Regrowth resumed during 9 days after removal. Sustained exposure also reduced intestinal renewal and altered intestinal architecture, limiting interpretation as a selectively beneficial regenerative intervention. [3]

Reversible inhibition of adult zebrafish fin regeneration

Animal study · Adult zebrafish after caudal-fin resection; 3–6 months in shared fin methods [3]

IWR-1 inhibited fin regeneration during exposure; regrowth resumed after compound removal. Exo-IWR-1 and IWR-frag did not reproduce inhibition in the specificity comparison.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Regenerative inhibition and recoveryQualitative imaging result Inhibition during exposure; regrowth 9 days after removal; four fish per group[3]

Conditions shared by the study groups

Route
Aquarium-water exposure
Frequency
Water and compound replenished daily
Treatment course
7 days with compound, then 9 days compound-free
Vehicle
DMSO; shared zebrafish methods specify 0.1% for intestinal experiments
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
IWR-1 treatment and washout
10 μM in water
DMSO carrier; exo and fragment comparators in Figure 5ASuppressed fin regrowth at day 7, with tissue regrowth after washout; Figure 6 reports four fish per group.[3]
IWR-1 treatment and washout
Model: Adult zebrafish after caudal-fin resection; 3–6 months in shared fin methods
Reported limits: No exact percentage recovery or measured systemic dose reported for this comparison.
Methods and source locations

Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1 (endo)

Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.

Figures 5A and 6 with captions; Results: Reversible chemical disruption of tissue regeneration; Methods: Zebrafish studies

Regenerative inhibition and recovery: Serial fin imaging; no exact regrowth percentage inferred — Figure 6 and caption; Figure 5A specificity controls

IWR-1 treatment and washout · Figures 5A and 6 with captions; Results: Reversible chemical disruption of tissue regeneration; Methods: Zebrafish studies

Intestinal renewal and tissue effects during sustained exposure

Animal study · Six-month-old zebrafish; mid-intestinal histology and BrdU incorporation [3]

IWR-1 reduced intestinal BrdU labeling after 8 days and altered intestinal architecture after 14 days. The authors also reported lethargy and decreased appetite after more than 5 days (data not shown).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intestinal renewal and histologyQualitative histology/BrdU result Reduced BrdU labeling at 8 days; architectural changes at 14 days[3]

Conditions shared by the study groups

Route
Aquarium-water exposure
Frequency
Water and compound replenished daily
Treatment course
8 or 14 days
Vehicle
DMSO; shared zebrafish methods specify 0.1% for intestinal experiments
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sustained IWR-1 exposure
10 μM in water
0.1% DMSOReduced BrdU labeling at 8 days and gross tissue changes at 14 days; eight animals per group stated in Figure 5C caption.[3]
Sustained IWR-1 exposure
Model: Six-month-old zebrafish; mid-intestinal histology and BrdU incorporation
Reported limits: Figure 5D used four scorers of sections from eight fish; scorers are not independent animal replicates.
Methods and source locations

Compound reported in the paper: IWR-1-endo; Compound label in the paper: IWR-1 (endo)

Applies to the paper-tested endo compound and stated model; no Adooq lot validation or salt conversion.

Figure 5C–D and caption; Results: Reversible chemical disruption of tissue regeneration; Methods: Zebrafish studies

Intestinal renewal and histology: Eight animals per group; four scorers assessed intestinal sections for Figure 5D; no bar-height decimal extraction — Figure 5C–D and caption

Sustained IWR-1 exposure · Figure 5C–D and caption; Results: Reversible chemical disruption of tissue regeneration; Methods: Zebrafish studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1127442-82-3
Applications Wnt inhibitor
Formula C25H19N3O3
Molecular Weight 409.44
SMILES
[H][C@@]12[C@@](C(N(C3=CC=C(C(NC4=CC=CC5=C4N=CC=C5)=O)C=C3)C2=O)=O)([H])[C@@H]6C=C[C@H]1C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 19 mg/mL (46.4 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Bao R, Christova T, Song S, et al. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells PloS one (2012). PMID: 23144924 DOI: 10.1371/journal.pone.0048670 Source material
  2. [2] Lu J, Ma Z, Hsieh JC, et al. Structure-activity relationship studies of small-molecule inhibitors of Wnt response Bioorganic & medicinal chemistry letters (2009). PMID: 19410457 DOI: 10.1016/j.bmcl.2009.04.040 Source material
  3. [3] Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer Nature chemical biology (2009). PMID: 19125156 DOI: 10.1038/nchembio.137 Source material

Publications

2 publications citing this product

  1. Yuichi Akaba, .et al. , iScience, 2025, Oct 16;28(11):113789 PMID: 41244585
  2. Charles A.Herring, .et al. , Cell, 2022, Oct 27;S0092-8674(22)01258-2 PMID: 36318921

Added to your cart

View Cart Checkout
Loading...